This year was full of scientific breakthroughs that directly benefited
cancer patients. Three of the most exciting innovations came in the form
of new treatment options for lymphoma, pancreatic cancer and
inflammatory breast cancer. 
These new treatments wouldn't have
been possible without patient participation in clinical trials. To learn
more about these treatments and clinical trials available at MD
Anderson see the stories below.
A Good Day for Patients With Lymphoma
7/2011
- Today, the Oncologic Drugs Advisory Committee, an FDA advisory panel,
voted 10-0 to recommend accelerated approval for Adcetris to treat
patients with relapsed Hodgkin lymphoma after having a stem cell transplant, and for patients with relapsed or resistant systemic ALCL.
Adcetris
(Brentuximab vedotin), which is made by Seattle Genetics, combines an
antibody that targets CD30 receptor with a toxic drug. This combination
is called Antibody Drug Conjugate (ADC, hence the first three letters in
the name Adcetris).
New Hope for Treating Pancreatic Cancer
Recently, a clinical trial published in the New England Journal of Medicine offered new hope for patients suffering from pancreatic cancer.
This trial enrolled more than 300 patients with advanced cancer of the pancreas, who were treated with either the standard chemotherapy with gemcitabine or with a four-drug chemotherapy combination called FOLFIRINOX.
Read the full article
Clinic Offers Novel Therapies for Inflammatory Breast Cancer PatientsThe Morgan Welch Inflammatory Breast Cancer Research Program and Clinic at MD Anderson is the first of its kind to focus on patients with inflammatory breast cancer (IBC). Since opening in October 2007, we've seen more than 300 IBC patients from across the country.
Treating IBC requires the coordinated efforts of every member of the oncology team. Our multidisciplinary team of experts in medical oncology, surgical oncology, radiation oncology, diagnostic radiology, pathology and IBC biology are passionate and committed to fighting IBC.
Read the full article
Leave a comment